Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trial programme
Latest Information Update: 31 Jan 2022
Price :
$35 *
At a glance
- Drugs Adavosertib (Primary) ; Capecitabine (Primary) ; Sapitinib (Primary) ; Aspirin; Bevacizumab; Cetuximab; Fluorouracil; Irinotecan; Mitogen-activated protein kinase kinase inhibitors; MTOR protein inhibitors; Oxaliplatin; Panitumumab; Panitumumab; Phosphatidylinositol 3 kinase alpha inhibitors; Proto-oncogene protein b-raf inhibitors; Proto-oncogene protein c-akt inhibitors
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms FOCUS4; FOCUS4-C; FOCUS4-N
- 26 Jan 2022 Status changed from discontinued to completed.
- 18 Sep 2021 Primary endpoint (FOCUS4-C Progression-free survival) has been met, according to Results published in the Journal of Clinical Oncology.
- 18 Sep 2021 Results (n=247) assessing findings of FOCUS4-C, which tested the safety and efficacy of adavosertib in patients with RAS/TP53-mut mCRC compared with active monitoring (AM) and has achieved disease stability following induction chemotherapy, published in the Journal of Clinical Oncology.